SCHEMBL644139

SCHEMBL644139

COC(=O)C1Cc2ccccc2N1S(=O)(=O)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
POLB P06746 3/20 0.47
PTGER3 P43115 1/20 0.46
DRD2 P14416 2/20 0.45
DRD4 P21917 2/20 0.45
LMNA P02545 5/20 0.44
NPSR1 Q6W5P4 2/20 0.44
MAPT P10636 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MEN1 O00255 1/20 0.43
GAA P10253 1/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
KMT2A Q03164 1/20 0.43
BDKRB1 P46663 3/20 0.42
HSD11B1 P28845 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL643004 0.86 ALDH1A1 (0.48) ALDH1A1L3MBTL1TDP1PTGER3LMNA
SCHEMBL2519672 0.84 ESR1 (0.56) ALDH1A1TDP1POLBPTGER3LMNA
SCHEMBL2519677 0.84 ESR1 (0.56) ALDH1A1TDP1POLBPTGER3LMNA
SCHEMBL644486 0.83 ALDH1A1 (0.52) ALDH1A1L3MBTL1TDP1POLBLMNA
SCHEMBL3588564 0.81 LMNA (0.47) ALDH1A1POLBPTGER3LMNANPSR1
SCHEMBL4843221 0.80 MMP8 (0.52) ALDH1A1POLBLMNANPSR1MAPT
SCHEMBL2489104 0.80 L3MBTL1 (0.47) ALDH1A1L3MBTL1TDP1POLBLMNA
SCHEMBL926563 0.79 NPSR1 (0.48) ALDH1A1L3MBTL1TDP1POLBPTGER3
SCHEMBL927220 0.79 BDKRB1 (0.51) PTGER3MEN1GAAKMT2ABDKRB1
SCHEMBL5847318 0.78 DRD2 (0.45) ALDH1A1POLBDRD2DRD4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119633-B2 N-{2-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-2-oxo-ethoxy]-ethyl}-N-ethyl-4-methoxy-2,3,6-trimethyl-phenylsulfonamide; condensing the N-carboxyalkyl phenylsulfonamide with the substituted piperidine; bradykinin receptor antagonists; analgesics; antidiabetics; angiogenesis inhibitors; rheumatic diseases GRUENENTHAL GMBH (DE) 2012-02-21 US disclosed
EP-2150530-B1 SUBSTITUTED SULFONAMIDE DERIVATIVES GRUENENTHAL GMBH (DE) 2011-10-26 EP disclosed
EP-2150530-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2010-02-10 EP disclosed
US-20080312231-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2008-12-18 US disclosed
WO-2008131947-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312231-A1 Substituted Sulfonamide Compounds SULT2A1, SULT1A1, SCN1A ALDH1A1 511/4885L3MBTL1 4857/4885TDP1 4140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.